Kenya expands HIV prevention options as Lenacapavir rollout begins Thursday

However, health experts say not everyone at risk of contracting HIV will qualify for the jab, which will be administered only to individuals who test negative and who have not had potential exposure t.....

✨ Key Highlights

Kenya is launching a new long-acting HIV prevention injection, Lenacapavir, on Thursday, February 26, 2026, as part of its strategy to eliminate new HIV infections by 2030.

The drug, Lenacapavir, is up to 96 per cent effective and will be administered once every six months.
The rollout is spearheaded by the Kenyan Ministry of Health, aiming to reach 47 counties in three phases.
Eligibility for Lenacapavir requires individuals to test negative for HIV and have had no potential exposure within the last 72 hours, with crucial disclosure of other medications needed to avoid harmful interactions.